BMO Capital Initiates Coverage on Amphastar Pharmaceuticals Inc(NASDAQ:AMPH). The shares have been rated Market Perform. The rating by BMO Capital was issued on Jun 29, 2016.
Amphastar Pharmaceuticals Inc (AMPH) made into the market gainers list on Fridays trading session with the shares advancing 0.99% or 0.16 points. Due to strong positive momentum, the stock ended at $16.28, which is also near the day’s high of $16.43. The stock began the session at $16.04 and the volume stood at 2,26,505 shares. The 52-week high of the shares is $18.3 and the 52 week low is $10.5. The company has a current market capitalization of $730 M and it has 4,48,45,680 shares in outstanding.
Amphastar Pharmaceuticals Inc(AMPH) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $59.37M. Analysts had an estimated revenue of $62.00M. Earnings per share were $0.12. Analysts had estimated an EPS of $-0.03.
Several Insider Transactions has been reported to the SEC. On Jun 17, 2016, Rong Zhou (EVP, Production Center) sold 1,551 shares at $15.85 per share price.Also, On Jun 13, 2016, Richard K Prins (director) sold 7,500 shares at $15.94 per share price.On Jun 13, 2016, Jason B. Shandell (President) sold 9,904 shares at $16.43 per share price, according to the Form-4 filing with the securities and exchange commission.
Amphastar Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing manufacturing marketing and selling technically-challenging generic and injectable and inhalation products. The Company has two operational segments: finished pharmaceutical products and active pharmaceutical ingredients (API products). The finished pharmaceutical products segment manufactures markets and distributes enoxaparin Cortrosyn naloxone lidocaine jelly as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 17 products and is developing a portfolio of approximately 13 generic and eight injectable and inhalation product candidates. In addition to its marketed products it has a pipeline of approximately 21 generic and product candidates in various stages of development which target a variety of indications.